What We’re Reading: Out-of-Pocket Costs for Inhalers; Birth Control Pill Available Online; Remote Patient Monitoring Challenges

AstraZeneca Caps Out-of-Pocket Costs for Inhalers Amid Drug Pricing Scrutiny

AstraZeneca announced plans to limit out-of-pocket expenses for its inhaled respiratory products to $35 per month in the US, mirroring a similar initiative by competitor Boehringer Ingelheim, according to Reuters. Amid growing political scrutiny over high drug prices, senators like Bernie Sanders have criticized leading inhaler manufacturers, prompting investigations into pricing disparities between the US and other countries. AstraZeneca's decision applies to its entire portfolio of respiratory products for patients who are underinsured or have no health coverage.

First OTC Birth Control Pill in the US Available for Online Purchase

The rollout of Opill, the first over-the-counter birth control pill approved in the US, began Monday through online sales, according to CNN. Priced at $19.99 for a 1-month supply, Opill’s manufacturer Perrigo say that it offers accessibility and affordability, with discreet packaging to prioritize consumer privacy. This availability is particularly beneficial for individuals in remote areas or facing barriers to accessing traditional health care services, providing greater control over reproductive health choices. Reproductive health experts hope that the online availability marks a significant step in expanding contraceptive access and empowering individuals to make informed decisions about their health.

Surge in Remote Patient Monitoring Raises Concerns Over Oversight and Evidence

The expansion of remote patient monitoring services, accelerated by the COVID-19 pandemic, has led to significant growth in Medicare billing for these services, raising concerns about oversight and evidence of their effectiveness, according to Kaiser Health News. While remote monitoring offers potential benefits in managing chronic illnesses and freeing up appointment time, experts warn of a lack of robust evidence and regulatory oversight. As Medicare payments for remote monitoring soar, questions linger about appropriate utilization, patient access, and safeguarding against fraud. CMS says the agency is balancing patient access to the new technology with the need to right fraud and ensure proper reimbursement.